A pilot double-blind placebo-controlled trial of pioglitazone as adjunctive treatment to risperidone: Effects on aberrant behavior in children with autism
- 1 September 2015
- journal article
- research article
- Published by Elsevier in Psychiatry Research
- Vol. 229 (1-2) , 181-187
Abstract
No abstract availableKeywords
Funding Information
- Tehran University of Medical Sciences to Prof. Shahin Akhondzadeh (16043)
This publication has 29 references indexed in Scilit:
- A Double-Blind Placebo Controlled Trial of Ginkgo biloba Added to Risperidone in Patients with Autistic DisordersChild Psychiatry & Human Development, 2012
- Non-Steroidal Anti-Inflammatory Drugs and Brain Inflammation: Effects on Microglial FunctionsPharmaceuticals, 2010
- Pioglitazone: side effect and safety profileExpert Opinion on Drug Safety, 2009
- RAR/RXR and PPAR/RXR signaling in neurological and psychiatric diseasesProgress in Neurobiology, 2008
- The Neurobiology of AutismBrain Pathology, 2007
- Pioglitazone as a therapeutic agent in autistic spectrum disorderMedical Hypotheses, 2007
- Peroxisome proliferator-activated receptor agonist regulation of glial activation: Relevance to CNS inflammatory disordersNeurochemistry International, 2006
- Searching for ways out of the autism maze: genetic, epigenetic and environmental cluesTrends in Neurosciences, 2006
- Genetic, Environmental and Immunologic Factors in the Etiology of Autism Spectrum DisordersNeuroembryology and Aging, 2003
- Plasma fatty acid levels in autistic childrenProstaglandins, Leukotrienes and Essential Fatty Acids, 2001